Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

Fig. 3

Utilization of novel therapies among patients that initiate subsequent melanoma treatment. n represents the number of patients initiating subsequent melanoma treatment; Of the 177 patients in the NIVO + IPI arm, 64 patients initiate a subsequent melanoma treatment of which 63% patients use one of the novel drugs. IPI ipilimumab monotherapy cohort; NIVO nivolumab monotherapy cohort; NIVO + IPI nivolumab + ipilimumab cohort; Dab dabrafenib; Dab + Tra dabrafenib + trametinib; Ipi ipilimumab; Other novel drugs nivolumab, nivolumab + ipilimumab, trametinib, vemurafenib + cobimetinib, binimetinib, encorafenib, binimetinib + encorafenib; Pem pembrolizumab; Vem vemurafenib

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us